🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHeart rate increase on GLP-1 — clinical significance assessment

Heart rate increase on GLP-1 — clinical significance assessment

Dr.CardioMD Wed, Jun 3, 2026 at 5:41 AM 2 replies 194 viewsPage 1 of 1
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Jun 3, 2026 at 5:41 AM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

The narrow version of the question is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Practical detail welcome, however dull — the duller the better.

46 16kim_atl_prep, sarah_TO, wendy_avl and 43 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jun 3, 2026 at 6:14 AM#2
Dr.CardioMD said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 59 pg/mL (normal, cardiac function preserved)
  • Lp(a): 59 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 154 to 99 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

45 15Dr.PulmRoch, maya_sedona, stefan_berlin and 42 others
Reply Quote Save Share Report
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
Jun 3, 2026 at 6:47 AM#3
BethLabQueen said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off losartan entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

44 14JenMemphis, pat_auckland, Dr.GastroMayo and 41 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
wanda_boise
Member
412
1,890
Aug 2024
Boise, ID
Jun 3, 2026 at 7:20 AM#4
Dr.CardioMD said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

43 13nick_SD_fit, ben_calgary, patPC_UT and 40 others
Reply Quote Save Share Report
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Jun 3, 2026 at 10:23 AM#5

Clinical perspective, offered as context rather than as advice.

Dr.CardioMD said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

42 12BethLabQueen, ChrisMacros, KetoKyle and 39 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register